PATH
Menu

PATH commissioned this report in an effort to evaluate whether dose-sparing, possibly through the intradermal (ID) route, could improve the availability of yellow fever vaccine globally. The authors identify and discuss potential benefits, possible obstacles, and associated costs of dose-sparing as a vaccine delivery strategy. In addition, the report includes an assessment of which settings would be most appropriate and to what extent novel ID delivery devices, such as needle-free disposable-syringe jet injectors, would help to facilitate its successful implementation.

Author(s): Hickling J, Jones R

Corporate author(s): Working in Tandem, PATH

Publication date: April 2013

Available materials

English

Yellow Fever Vaccination

2,035 KB PDF

Hard copies are not available.

Some digital files may be saved at low resolutions to conserve file size. Versions with higher quality may be available; see the contact information below to enquire.

Region: Global

See also:

Vaccines and immunizationMiscellaneous

Health technologiesVaccine delivery

For more information…

Contact: PATH Publications
Email: publications@path.org
Mailing address: PATH, PO Box 900922, Seattle, WA 98109 USA